406 related articles for article (PubMed ID: 26916570)
21. The paradox of bleeding and thrombosis in thrombocythemia: is von Willebrand factor the link?
van Genderen PJ; Leenknegt H; Michiels JJ
Semin Thromb Hemost; 1997; 23(4):385-9. PubMed ID: 9263356
[TBL] [Abstract][Full Text] [Related]
22. Philadelphia-Negative Myeloproliferative Neoplasms Around the COVID-19 Pandemic.
Barbui T; De Stefano V
Curr Hematol Malig Rep; 2021 Oct; 16(5):455-463. PubMed ID: 34586561
[TBL] [Abstract][Full Text] [Related]
23. Biological rationale and clinical use of interferon in the classical BCR-ABL-negative myeloproliferative neoplasms.
Stein BL; Tiu RV
J Interferon Cytokine Res; 2013 Apr; 33(4):145-53. PubMed ID: 23570380
[TBL] [Abstract][Full Text] [Related]
24. Deamino-8-D-arginine vasopressin shortens the bleeding time in uremia.
Mannucci PM; Remuzzi G; Pusineri F; Lombardi R; Valsecchi C; Mecca G; Zimmerman TS
N Engl J Med; 1983 Jan; 308(1):8-12. PubMed ID: 6401193
[TBL] [Abstract][Full Text] [Related]
25. Myeloproliferative neoplasia: a review of clinical criteria and treatment.
Koopmans SM; van Marion AM; Schouten HC
Neth J Med; 2012 May; 70(4):159-67. PubMed ID: 22641623
[TBL] [Abstract][Full Text] [Related]
26. Retrospective review of the management of elective surgery with desmopressin and clotting factor concentrates in patients with von Willebrand disease.
Nitu-Whalley IC; Griffioen A; Harrington C; Lee CA
Am J Hematol; 2001 Apr; 66(4):280-4. PubMed ID: 11279640
[TBL] [Abstract][Full Text] [Related]
27. Myeloproliferative neoplasms working group consensus recommendations for diagnosis and management of primary myelofibrosis, polycythemia vera, and essential thrombocythemia.
Agarwal MB; Malhotra H; Chakrabarti P; Varma N; Mathews V; Bhattacharyya J; Seth T; Gayathri K; Menon H; Subramanian PG; Sharma A; Bhattacharyya M; Mehta J; Vaid AK; Shah S; Aggarwal S; Gogoi PK; Nair R; Agarwal U; Varma S; Prasad SV; Manipadam MT
Indian J Med Paediatr Oncol; 2015; 36(1):3-16. PubMed ID: 25810569
[TBL] [Abstract][Full Text] [Related]
28. Advances in the molecular characterization of Philadelphia-negative chronic myeloproliferative disorders.
Pikman Y; Levine RL
Curr Opin Oncol; 2007 Nov; 19(6):628-34. PubMed ID: 17906464
[TBL] [Abstract][Full Text] [Related]
29. Causes, etiology and diagnosis of acquired von Willebrand disease: a prospective diagnostic workup to establish the most effective therapeutic strategies.
Sucker C; Michiels JJ; Zotz RB
Acta Haematol; 2009; 121(2-3):177-82. PubMed ID: 19506364
[TBL] [Abstract][Full Text] [Related]
30. Cerebral vein thrombosis in patients with Philadelphia-negative myeloproliferative neoplasms. An European Leukemia Net study.
Martinelli I; De Stefano V; Carobbio A; Randi ML; Santarossa C; Rambaldi A; Finazzi MC; Cervantes F; Arellano-Rodrigo E; Rupoli S; Canafoglia L; Tieghi A; Facchini L; Betti S; Vannucchi AM; Pieri L; Cacciola R; Cacciola E; Cortelezzi A; Iurlo A; Pogliani EM; Elli EM; Spadea A; Barbui T
Am J Hematol; 2014 Nov; 89(11):E200-5. PubMed ID: 25042466
[TBL] [Abstract][Full Text] [Related]
31. Chronic kidney disease in patients with the Philadelphia-negative chronic myeloproliferative neoplasms.
Christensen AS; Møller JB; Hasselbalch HC
Leuk Res; 2014 Apr; 38(4):490-5. PubMed ID: 24630365
[TBL] [Abstract][Full Text] [Related]
32. Cytogenetics in the management of Philadelphia-negative myeloproliferative neoplasms: an update by the Groupe francophone de cytogénétique hématologique (GFCH).
Bilhou-Nabéra C; Bidet A; Eclache V; Lippert E; Mozziconacci MJ
Ann Biol Clin (Paris); 2016 Oct; 74(5):517-523. PubMed ID: 27477946
[TBL] [Abstract][Full Text] [Related]
33. [Periprocedural management of hemostasis risk in interventional radiology].
Potet J; Weber-Donat G; Thome A; Valbousquet L; Peroux E; Konopacki J; Baccialone J; Teriitehau CA
J Radiol; 2011; 92(7-8):659-70. PubMed ID: 21819908
[TBL] [Abstract][Full Text] [Related]
34. The JAK2 V617F mutational status and allele burden may be related with the risk of venous thromboembolic events in patients with Philadelphia-negative myeloproliferative neoplasms.
Borowczyk M; Wojtaszewska M; Lewandowski K; Gil L; Lewandowska M; Lehmann-Kopydłowska A; Kroll-Balcerzak R; Balcerzak A; Iwoła M; Michalak M; Komarnicki M
Thromb Res; 2015 Feb; 135(2):272-80. PubMed ID: 25559461
[TBL] [Abstract][Full Text] [Related]
35. Pathogenesis and Management of Thrombotic Disease in Myeloproliferative Neoplasms.
Arachchillage DR; Laffan M
Semin Thromb Hemost; 2019 Sep; 45(6):604-611. PubMed ID: 31382304
[TBL] [Abstract][Full Text] [Related]
36. Acquired von Willebrand syndrome: is it an extremely rare disorder or do we see only the tip of the iceberg?
Federici AB
J Thromb Haemost; 2008 Apr; 6(4):565-8. PubMed ID: 18221357
[No Abstract] [Full Text] [Related]
37. Coagulation and transfusion in the postoperative bleeding patient.
Kozek-Langenecker SA
Curr Opin Crit Care; 2014 Aug; 20(4):460-6. PubMed ID: 24933407
[TBL] [Abstract][Full Text] [Related]
38. Polycythemia vera and essential thrombocythemia: 2012 update on diagnosis, risk stratification, and management.
Tefferi A
Am J Hematol; 2012 Mar; 87(3):285-93. PubMed ID: 22331582
[TBL] [Abstract][Full Text] [Related]
39. Genomic aberrations of myeloproliferative and myelodysplastic/myeloproliferative neoplasms in chronic phase and during disease progression.
Hahm C; Huh HJ; Mun YC; Seong CM; Chung WS; Huh J
Int J Lab Hematol; 2015 Apr; 37(2):181-9. PubMed ID: 24845343
[TBL] [Abstract][Full Text] [Related]
40. A new era for IFN-α in the treatment of Philadelphia-negative chronic myeloproliferative neoplasms.
Hasselbalch HC
Expert Rev Hematol; 2011 Dec; 4(6):637-55. PubMed ID: 22077528
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
